Editorial comment on 'A novel approach indirectly comparing benefit: risk across oral antithrombotic therapies in patients with atrial fibrillation'. Are the evidences of current dose-adjusted anticoagulation with warfarin stroke prevention for patients with atrial fibrillation sufficient enough to compare with newly developed non-vitamin K oral anticoagulants?
- PMID: 27533975
- DOI: 10.1093/ehjcvp/pvu017
Editorial comment on 'A novel approach indirectly comparing benefit: risk across oral antithrombotic therapies in patients with atrial fibrillation'. Are the evidences of current dose-adjusted anticoagulation with warfarin stroke prevention for patients with atrial fibrillation sufficient enough to compare with newly developed non-vitamin K oral anticoagulants?
Erratum in
-
Erratum.Eur Heart J Cardiovasc Pharmacother. 2016 Oct;2(4):217. doi: 10.1093/ehjcvp/pvv055. Epub 2016 Jan 20. Eur Heart J Cardiovasc Pharmacother. 2016. PMID: 27600903 No abstract available.
Publication types
LinkOut - more resources
Full Text Sources
